Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.

Karol Mateusz PencinaRodrigo ValderrabanoBenjamin WipperAriela R OrkabyKieran F ReidThomas StorerAlexander P LinSai MerugumalaLauren WilsonNancy LathamCatherine Ghattas-PuylaraNoelle E OzimekMing ChengAvantika BhargavaYusnie Memish-BelevaBrian LawneySiva LavuPamela M SwainRajendra S ApteDavid A SinclairDavid LivingstonShalender Bhasin

Published in: The Journal of clinical endocrinology and metabolism (2023)

MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.

Keyphrases

physical activity
weight loss
body weight
blood pressure
adipose tissue
metabolic syndrome
bariatric surgery
type diabetes
left ventricular
electronic health record
soft tissue
heart rate
body mass index
skeletal muscle
hypertensive patients
glycemic control
ejection fraction
atrial fibrillation
blood glucose